You are here: Media
Newsletter signup
Click here to sign up for news and updates.
Press Releases
Elan Drug Technologies Announces Pivotal Phase 3 Trial for Hydrocodone Controlled Release Fomulation by its Licensing Partner Zogenix Inc
DUBLIN, IRELAND, March 18, 2010, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today ...
Elan Drug Technologies Welcomes the Launch of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets
AMPYRA™ Uses Elan’s Proprietary MXDAS™ (Matrix Drug Absorption System) Drug Delivery Technology ...
Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA™ (Dalfampridine) Extended Release Tablets
AMPYRA™ Approved Using Elan’s Proprietary MXDAS™ (Matrix Drug Absorption System) Drug Delivery Technology ...
Calendar of Events
October 5-7
CPhI Worldwide Annual Meeting
...
November 14-18
AAPS Annual Meeting and Exposition / FIP2010 World Congress
...
November 15-17
BioEurope 2010
...
Key Facts
Corporate fact sheet
A high level look at Elan Drug Technologies
past, present and future.
More information
Commercialised products
Information on Elan Drug Technologies
commercialised products.
More information
© 2009, Elan Drug Technologies, Monksland, Athlone, Co Westmeath, Ireland
Tel: +353 9064 95000 | Email: edtqueries@elan.com | Trademarks | Privacy policy | Terms of Use | 
Elan Corporation, plc. Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland. Registered in Ireland, Number 30356.